134 related articles for article (PubMed ID: 37245712)
21. Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography.
Kim G; Yu TY; Jee JH; Bae JC; Kang M; Kim JH
Diabetes Metab; 2024 May; 50(3):101534. PubMed ID: 38608865
[TBL] [Abstract][Full Text] [Related]
22. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
23. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.
Hagström H; Talbäck M; Andreasson A; Walldius G; Hammar N
J Hepatol; 2020 Nov; 73(5):1023-1029. PubMed ID: 32621944
[TBL] [Abstract][Full Text] [Related]
24. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
25. Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study.
Park H; Dawwas GK; Liu X; Nguyen MH
J Intern Med; 2019 Dec; 286(6):711-722. PubMed ID: 31359543
[TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study.
Fujii H; Iwaki M; Hayashi H; Toyoda H; Oeda S; Hyogo H; Kawanaka M; Morishita A; Munekage K; Kawata K; Yamamura S; Sawada K; Maeshiro T; Tobita H; Yoshida Y; Naito M; Araki A; Arakaki S; Kawaguchi T; Noritake H; Ono M; Masaki T; Yasuda S; Tomita E; Yoneda M; Kawada N; Tokushige A; Kamada Y; Takahashi H; Ueda S; Aishima S; Sumida Y; Nakajima A; Okanoue T;
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):370-379. PubMed ID: 35051649
[TBL] [Abstract][Full Text] [Related]
27. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis.
Balakrishnan M; Patel P; Dunn-Valadez S; Dao C; Khan V; Ali H; El-Serag L; Hernaez R; Sisson A; Thrift AP; Liu Y; El-Serag HB; Kanwal F
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):61-71.e15. PubMed ID: 32360810
[TBL] [Abstract][Full Text] [Related]
28. Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.
Huang DQ; Wilson LA; Behling C; Kleiner DE; Kowdley KV; Dasarathy S; Amangurbanova M; Terrault NA; Diehl AM; Chalasani N; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J; ; Loomba R
Gastroenterology; 2023 Aug; 165(2):463-472.e5. PubMed ID: 37127100
[TBL] [Abstract][Full Text] [Related]
29. Risk of severe COVID-19 and mortality in patients with established chronic liver disease: a nationwide matched cohort study.
Simon TG; Hagström H; Sharma R; Söderling J; Roelstraete B; Larsson E; Ludvigsson JF
BMC Gastroenterol; 2021 Nov; 21(1):439. PubMed ID: 34814851
[TBL] [Abstract][Full Text] [Related]
30. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.
Yılmaz Y; Kanı HT; Demirtaş CÖ; Kaya E; Sapmaz AF; Qutranji L; Alkayyali T; Batun KD; Batman M; Toy B; Çiftaslan A
Turk J Gastroenterol; 2019 Oct; 30(10):892-898. PubMed ID: 31258138
[TBL] [Abstract][Full Text] [Related]
31. Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.
Simon TG; Ebrahimi F; Roelstraete B; Hagström H; Sundström J; Ludvigsson JF
Cardiovasc Diabetol; 2023 Dec; 22(1):343. PubMed ID: 38093277
[TBL] [Abstract][Full Text] [Related]
32. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
[TBL] [Abstract][Full Text] [Related]
33. Risk of infections and their role on subsequent mortality in biopsy-proven alcohol-related liver disease.
Hagström H; Thiele M; Simon TG; Sharma R; Röckert Tjernberg A; Roelstraete B; Söderling J; Ludvigsson JF
United European Gastroenterol J; 2022 Mar; 10(2):198-211. PubMed ID: 35088575
[TBL] [Abstract][Full Text] [Related]
34. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
[TBL] [Abstract][Full Text] [Related]
35. The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan.
Lin CL; Tai CM; Huang JF; Liu CJ; Chen HF; Cheng PN; Chen CY; Peng CY; Wang CC; Weng SH; Tseng TC; Kao JH
J Gastroenterol Hepatol; 2022 Oct; 37(10):1901-1910. PubMed ID: 35790343
[TBL] [Abstract][Full Text] [Related]
36. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis.
Aminian A; Al-Kurd A; Wilson R; Bena J; Fayazzadeh H; Singh T; Albaugh VL; Shariff FU; Rodriguez NA; Jin J; Brethauer SA; Dasarathy S; Alkhouri N; Schauer PR; McCullough AJ; Nissen SE
JAMA; 2021 Nov; 326(20):2031-2042. PubMed ID: 34762106
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis.
Pelusi S; Cespiati A; Rametta R; Pennisi G; Mannisto V; Rosso C; Baselli G; Dongiovanni P; Fracanzani AL; Badiali S; Maggioni M; Craxi A; Fargion S; Prati D; Nobili V; Bugianesi E; Romeo S; Pihlajamaki J; Petta S; Valenti L
Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2310-2319.e6. PubMed ID: 30708111
[TBL] [Abstract][Full Text] [Related]
38. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.
Baratta F; Pastori D; Angelico F; Balla A; Paganini AM; Cocomello N; Ferro D; Violi F; Sanyal AJ; Del Ben M
Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2324-2331.e4. PubMed ID: 31887443
[TBL] [Abstract][Full Text] [Related]
39. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
[TBL] [Abstract][Full Text] [Related]
40. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
Angulo P; Kleiner DE; Dam-Larsen S; Adams LA; Bjornsson ES; Charatcharoenwitthaya P; Mills PR; Keach JC; Lafferty HD; Stahler A; Haflidadottir S; Bendtsen F
Gastroenterology; 2015 Aug; 149(2):389-97.e10. PubMed ID: 25935633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]